Cancer immunology, immunotherapy : CII · 2026
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.
СтатьяМногоцентровое исследованиеОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amrane Karim, Campedel Luca, Moinard-Butot Fabien, Gout Mathilde, Mahammedi Hakim, Bennamoun Mostefa, Herrmann Tressie, Gabriel Pierre-Etienne, Pouessel Damien, Roulleaux-Dugage Matthieu, Thibault Constance, Cancel Mathilde, Flechon Aude, Huillard Olivier, Abbar Baptiste, Borchiellini Delphine, Doublet Louis, Augusto-Pelegrin Laëtitia, Boughalem Elouen, Cornillon Pierre, Dumont Clément, Barthélémy Philippe
Аннотация
BACKGROUND: Histologic variants (HV) of urothelial carcinoma (UC-V) and non-urothelial carcinomas (NUC) of the bladder and urinary tract are aggressive malignancies with poor prognosis and limited response to platinum-based chemotherapy. Despite their biological particularities and distinct immune microenvironments, these HV subtypes are under-represented in immune checkpoint blockade (ICB) trials.
METHODS: PEMBROBLAD is a French national multicenter retrospective study conducted across 24 centers. We included patients with advanced UC-V or NUC who received second-line anti-PD-(L)1 monotherapy after progression on platinum-based chemotherapy between 2016 and 2022. Primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), objective response rate (ORR) and safety.
RESULTS: We included 129 UC-V and 34 NUC. With a median follow-up was 21.9 months, the median OS was 8.6 [95% confidence interval (CI), 5.3-11.2] months, with 8.5 [95% CI 5.3-10.9] months for UC-V and 10.5[95% CI 3.5-22.8] months for NUC. The median PFS was 2.6 [95% CI 2.1-3.4] months with 2.5 [95% CI 2.0-3.4] months for the UC-V group and 2.6 [2.0-3.4] months for the NUC group. ORR was 31.4% overall (complete response 15.3%, partial response 16.1%). In multivariable analysis, ECOG performance status ≥ 2 was independently associated with both poorer OS (HR 3.30, 95% CI 1.22-8.92; p = 0.018) and PFS (HR 2.32, 95% CI 1.52-3.54; p < 0.001). Pembrolizumab treatment was associated with improved PFS (HR 0.53, 95% CI 0.31-0.81; p = 0.017). Grade ≥ 3 immune-related adverse events occurred in 10.8% of patients, with no treatment-related deaths.
CONCLUSIONS: Anti-PD-(L)1 monotherapy shows clinical benefit in advanced UC-V and NUC after platinum failure.
METHODS: PEMBROBLAD is a French national multicenter retrospective study conducted across 24 centers. We included patients with advanced UC-V or NUC who received second-line anti-PD-(L)1 monotherapy after progression on platinum-based chemotherapy between 2016 and 2022. Primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), objective response rate (ORR) and safety.
RESULTS: We included 129 UC-V and 34 NUC. With a median follow-up was 21.9 months, the median OS was 8.6 [95% confidence interval (CI), 5.3-11.2] months, with 8.5 [95% CI 5.3-10.9] months for UC-V and 10.5[95% CI 3.5-22.8] months for NUC. The median PFS was 2.6 [95% CI 2.1-3.4] months with 2.5 [95% CI 2.0-3.4] months for the UC-V group and 2.6 [2.0-3.4] months for the NUC group. ORR was 31.4% overall (complete response 15.3%, partial response 16.1%). In multivariable analysis, ECOG performance status ≥ 2 was independently associated with both poorer OS (HR 3.30, 95% CI 1.22-8.92; p = 0.018) and PFS (HR 2.32, 95% CI 1.52-3.54; p < 0.001). Pembrolizumab treatment was associated with improved PFS (HR 0.53, 95% CI 0.31-0.81; p = 0.017). Grade ≥ 3 immune-related adverse events occurred in 10.8% of patients, with no treatment-related deaths.
CONCLUSIONS: Anti-PD-(L)1 monotherapy shows clinical benefit in advanced UC-V and NUC after platinum failure.